Corporate
June 2013
12/06/13
Bioniche Founder and CEO Addresses Shareholders
May 2013
29/05/13
Bioniche Responds to Dissident Shareholders and Rejects Call for Early Shareholder Meeting
April 2013
22/04/13
Bioniche Life Sciences Inc. Responds to Letter from Former Biovail Executives
January 2013
30/01/13
Bioniche Life Sciences Inc. Terminates its License Agreement with Trophogen Inc.
December 2012
06/12/12
Bioniche Life Sciences Inc. Announces a Change to its Board of Directors
July 2012
30/07/12
Bioniche Life Sciences Inc. Appoints an Independent Chairman of its Board of Directors
November 2011
09/11/11
Bioniche Life Sciences Inc. Holds Annual & Special Meeting of Shareholders
October 2011
20/10/11
New York Court Grants Summary Judgment in Favour of Bioniche Life Sciences Inc.
September 2011
29/09/11
Bioniche Life Sciences Inc. Launches Three New Products
August 2011
01/08/11
Bioniche Life Sciences Inc. Will Not Proceed With Business and Asset Acquisition of Plasvacc Holdings Limited
July 2011
04/07/11
Bioniche Life Sciences Inc. has Agreed to Acquire Plasvacc Holdings Limited of Australia
March 2011
31/03/11
Folltropin®-V - a Key Bioniche Animal Health Product - Receives Marketing Authorization in China
January 2011
03/01/11
Bioniche Announces Reorganization of Leadership Team
December 2010
21/12/10
Bioniche Animal Health and IMV Technologies Sign European Distribution Agreement
06/12/10
Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia
October 2010
28/10/10
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada for a Second Time
August 2010
25/08/10
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology
June 2010
17/06/10
Bioniche Strengthens its International Patent Portfolio for its MCC & Oligonucleotide Technology Platforms
April 2010
19/04/10
Bioniche Receives FedDev Ontario Investment to Support Fermentation Scale-Up for New Vaccine Manufacturing Centre
August 2009
05/08/09
Bioniche Announces Resignation of its CFO
June 2009
22/06/09
Bioniche Provides a Corporate Update
April 2009
27/04/09
Bioniche Provides a Corporate Update
May 2008
23/05/08
Bioniche Presents Pre-Clinical Research at Two International Conferences
April 2008
18/04/08
Bioniche Reports the Passing of its Board Chair
February 2008
08/02/08
Bioniche Receives $5 Million Capital Financing Support to Scale-up E. coli O157:H7 Vaccine Production
December 2007
20/12/07
Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
18/12/07
Bioniche Receives $10 Million of Provincial Government Support to Scale-up Vaccine Production in Ontario
17/12/07
Announcement Planned by Ontario Ministry of Economic Development and Trade
04/12/07
Bioniche Recognized as One of the Top 10 Life Science Companies in Canada
November 2007
15/11/07
Bioniche Presents at Annual Convention of Canadian Association of Fairs & Exhibitions
06/11/07
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
October 2007
05/10/07
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
04/10/07
Bioniche to Present at BioContact Quebec 2007
September 2007
10/09/07
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial
July 2007
19/07/07
Bioniche Appoints New Animal Health and Food Safety Leadership Team
18/07/07
Bioniche Appoints New Director to its Board
May 2007
01/05/07
Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases
March 2007
30/03/07
Bioniche Recognized with Québec Biotechnology Award
29/03/07
Bioniche and Technology Partnerships Canada Amend Agreement on MCC Research Project
02/03/07
Bioniche Files Final Short-Form Prospectus for Offering of Units
February 2007
09/02/07
Bioniche Files Preliminary Short-Form Prospectus for Offering of Units
January 2007
12/01/07
Bioniche Further Pays Down Debt with Laurus Master Funds
December 2006
22/12/06
Bioniche Further Pays Down Debt
08/12/06
Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group
November 2006
07/11/06
Bioniche Plans to Liquidate Two Remaining Assets Associated with Irish Pharma Group
October 2006
31/10/06
Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference
02/10/06
Bioniche Board Approves a Shareholders Rights Plan
September 2006
29/09/06
Bioniche Life Sciences Inc. Re-Files its 2005 MD&A and Certificates
June 2006
27/06/06
Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development
March 2006
22/03/06
Updates on MCC Phase III Bladder Cancer Study and E. coli O157:H7 Cattle Vaccine Regulatory Progress
February 2006
01/02/06
Bioniche and RoundTable Healthcare Partners Close Sale of Bioniche Pharma Group Ltd.
January 2006
12/01/06
Bioniche Signs Definitive Purchase Agreement for Sale of Pharma Group to RoundTable Healthcare Partners
October 2005
28/10/05
Bioniche Clarifies Terms of Pharma Group Sale and Private Placement
18/10/05
Bioniche Pharma Group and AngioDynamics Sign Exclusive Distribution Agreement for Sotradecol(R) Injection
05/10/05
Bioniche and ICC Private Equity Fund Agree to Sell Bioniche Pharma Group to RoundTable Healthcare Partners
04/10/05
Bioniche Retains Blackmont Capital to Assist in the Sale of its Pharma Business Unit
September 2005
26/09/05
Bioniche in Good Standing with Technology Partnerships Canada (TPC)
July 2005
12/07/05
Bioniche Reports Positive News from BetacTM Product Recall Investigation
June 2005
20/06/05
Bioniche Life Sciences Retains GCI Group as Strategic Investor Relations Counsel
13/06/05
Bioniche Appoints New Chief Medical Officer to Advance Clinical Trials
01/06/05
Bioniche Pharma Group and Grünenthal Sign Exclusive Agreement for Distribution of Suplasyn®
May 2005
17/05/05
Bioniche Granted Additional Patent for Mycobacterial Cell Wall Technology
13/05/05
Bioniche Announces Change in Board of Directors Composition
04/05/05
Bioniche to Present at Rodman & Renshaw
March 2005
29/03/05
Bioniche Granted European Patent for MCC in Bladder Cancer
22/03/05
Bioniche Presents Further Data on Mycobacterial Cell Wall-DNA Complex (MCC) at European Association of Urology 20th Congress
December 2004
23/12/04
Bioniche Animal Health Appoints New Leaders of European and Australian/Asian Operations
06/12/04
Senior Personnel Change at Bioniche
November 2004
18/11/04
New Data Confirms Unique Anticancer Activity Profile
08/11/04
New Studies Demonstrate Anti-Cancer Activity of Bioniche Technology Against Canine Cancer
04/11/04
Bioniche Reports First Quarter Results for Fiscal 2005
October 2004
06/10/04
Bioniche Expands its Intellectual Property Portfolio
September 2004
23/09/04
Bioniche Presents Data on Cystistat and Launches Product Web Site at Inaugural Multinational Interstitial Cystitis Association Annual Meeting
20/09/04
Bioniche Appoints a Chief Operating Officer
August 2004
26/08/04
Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News
June 2004
14/06/04
Bioniche Serves Community Needs Through New Pet Loss Program
08/06/04
Bioniche Ranked Among Canada’s Top 100 Fastest-Growing Companies by PROFIT Magazine
01/06/04
Bioniche Retains The Anne McBride Company Inc.
|
